TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Milnacipran on Pain in Fibromyalgia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female age 18 or older~* Written informed consent and written release of health and research study information~* Diagnosis of Fibromyalgia~* Participant has pain greater than 4 on the NRS of 0 to 10 on average over the last week prior to initial evaluation that interferes with function most days per week~* Pain duration greater than 6 months~* Negative urine pregnancy test on experimental day 1 and 2 and on first day of treatment prior to administration of study medication and fluoroscopy~* Ability to speak and understand English, to follow instructions, and fill out study questionnaires~* Likely to complete all required visits~* Must be ambulatory and able to lay prone for 30 minutes~Exclusion Criteria:~* Any condition or situation that in the investigator's opinion may put the participant at significant risk, confound the study results, or interfere significantly with the participant's participation in the study~* Serious, unstable medical illness that could lead to hospitalization over the next three months; and/or a DSM-IV diagnosis(es) with active problems within the last six months, such as: schizophrenia, bipolar disorder, antisocial personality disorder, or substance use disorder~* Known, uncontrolled, serious systemic disease, including: hypertension and/or tachyarrythmia~* Females who are pregnant, breast feeding, or who plan to become pregnant, or who may potentially become pregnant~* Allergy or sensitivity to any component of the study medication or to contrast dye~* Patients on coumadin, heparin, or any other known increase risk of bleeding~* Signs of increased intracranial pressure~* Patients who are unable to continue current pain medication~* Allergy or contraindication to acetaminophen~* Use of monoamine oxidase inhibitors~* Uncontrolled narrow-angle glaucoma

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Titrated Milnacipram doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Infection with HCV genotype 1, 4, 5, or 6~* Cirrhosis determination~* Subject met the following classifications:~  * Treatment-naive~ * Screening laboratory values within defined thresholds~ * Not treated with any investigational drug or device within 30 days of screening~* Use of highly effective contraception methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Prior exposure to an direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase~* Pregnant or nursing female, or male with pregnant female partner~* Current or prior history of clinical hepatic decompensation~* History of clinically-significant illness or any other major medical disorder that may have interfered with subject treatment, assessment, or compliance with the protocol~* Excessive alcohol ingestion or significant drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sofosbuvir+PEG+RBV (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Evidence of a personally signed and dated ICD indicating that the parent(s)/legal guardian has been informed of all pertinent aspects of the study.~* Aged 6 weeks (42 days) to \<6 years at the time of consent.~* Healthy infants and children as determined by medical history, physical examination, and judgment of the investigator.~Exclusion Criteria:~* Participation in other studies involving investigational drug(s)/vaccine(s) since birth (Cohort 1 only) or in the 6 months prior to study entry (Cohorts 2, 3, and 4) and/or during study participation.~* Other acute or chronic medical or psychiatric condition, including recent laboratory abnormality, that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.~* Vaccination with licensed or investigational pneumococcal vaccine.~* Previous vaccination with licensed or investigational Hib vaccine.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- 13-valent Pneumococcal Conjugate Vaccine (13vPnC) (Type: EXPERIMENTAL): 1. Participants in cohort 1 will receive each dose of 13vPnC in months 2, 4 and 6, and then a booster dose during months 12-15.~2. Participants in cohort 2 will receive first dose dose 13vPnC at the age of months 7(included) to months 12 (less than months 12), and the second dose will be given at least 28 days after first dose, and the third dose will be months 12 to 15 (and at least 56 days after the second dose).~3. Participants in cohort 3 will receive the first dose of 13vPnC during 1 (included) to 2 years (less than 2 years of age) of age, and the second dose will be given at least 56 days after first dose.~4. Participants in cohort 4 will receive only one dose at the age of 2 (included) to 6 (less than 6 years of age) years of age.
- Haemophilus influenzae type b (Hib) (Type: ACTIVE_COMPARATOR): 1. No participants in cohort 1 will receive Hib vaccine.~2. Participants in cohort 2 will receive the first dose of Hib vaccine at the age of months 7 (included) to 12 (less than 12 months), and the second dose will be given at least 28 days after the first dose, the third dose will following local practice or national recommendation at the discretion of the investigator.~3. Participants in cohorts 3 and 4 will receive the only one dose Hib vaccine at the age of 1 (included) to 6 (less than 6 years) years of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi Arabia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)~* The decision to initiate treatment with commercially available Tresiba® has been made by the patient/legally acceptable representative and the treating physician before and independently from the decision to include the patient in this study~* Male or female, age above or equal to 18 years at the time of signing informed consent~* Diagnosed with type 2 diabetes and treated with any antihyperglycaemic medication(s), except Tresiba®, for at least 26 weeks prior to Informed consent and Initiation Visit (Visit 1)~* Available and documented HbA1c value measured within the last 12 weeks prior to initiation of Tresiba® treatment~Exclusion Criteria:~* Previous participation in this study. Participation is defined as having given informed consent in this study~* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation~* Hypersensitivity to the active substance or to any of the excipients as specified in the Tresiba® local label

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tresiba® (Type: None): Patients with type 2 diabetes in Saudi Arabia are to receive Tresiba® (Insulin degludec) for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clobazam in Subjects With Lennox-Gastaut Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subject must have been \<11 years of age at the onset of LGS~* Subject must have LGS~* Subject must be on at least 1 stable dose AED~* Parent or caregiver must be able to keep an accurate seizure diary~Key Exclusion Criteria:~* Etiology of subject's seizures is a progressive neurologic disease. Subjects with tuberous sclerosis will not be excluded from study participation~* Subject has had an episode of status epilepticus within 12 weeks of baseline~* Subject has had an anoxic episode requiring resuscitation within 1 year of screening~* Subject has had a clinically significant history of an allergic reaction or significant sensitivity to benzodiazepines~* Subject is taking more than 3 concurrent AEDs. Note: Vagal Nerve Stimulation (VNS) or ketogenic diet is allowed and each will be counted as one of the three allowed AEDs~* If the subject is on the ketogenic diet, has been for less than 4 weeks prior to screening or suffers from frequent stooling~* If the subject has a VNS, the settings have not been stable for at least 4 weeks prior to screening~* Subject has taken corticotropins in the 6 months prior to screening~* Subject is currently taking long-term systemic steroids (excluding inhaled medication for asthma treatment) or any other daily medication known to exacerbate epilepsy. An exception will be made of prophylactic medication, for example, for urinary tract infections or asthma~* If the subject is taking felbamate, has been taking it for less than 1 year prior to screening or previous treatment with felbamate resulted in withdrawal due to liver or bone marrow adverse events

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Clobazam Low Dose (Type: EXPERIMENTAL): None
- Clobazam High Dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria~1. Diagnosis of metastatic or advanced cancer that has failed standard effective therapy~2. Life expectancy of at least 12 weeks and adequate performance status~3. Adequate bone marrow, kidney and liver function~4. Willingness of male and female subjects who are not surgically sterile or post-menopausal to use adequate methods of birth control~Exclusion Criteria~1. Any anticancer chemotherapy, radiotherapy immunotherapy or investigational agents within 4 weeks of first dose of HKI-272~2. Inadequate cardiac function~3. Surgery within 2 weeks of first dose of HKI-272~4. Active central nervous system metastases (i.e., symptomatic, required use of corticosteroids and/or progressive growth)~5. Significant gastrointestinal disorder with diarrhea as a major symptom~6. Pregnant or breast feeding women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neratinib 80 mg (Type: EXPERIMENTAL): None
- Neratinib 160 mg (Type: EXPERIMENTAL): None
- Neratinib 240 mg (Type: EXPERIMENTAL): None
- Neratinib 320 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Dexmedetomidine on Prevention of Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. the patients undergoing ascending, arch and/or proximal descending aorta surgery with cardiopulmonary bypass~2. 20 - 100 yrs old~Exclusion Criteria:~1. having preoperative severe renal dysfunction (eGFR \< 15 ml/min per 1.73m2)~2. Left ventricular-ejection fraction \< 30%~3. Preexisting congestive heart failure~4. Severe coronary artery disease~5. Hemodynamically unstable arrhythmia~6. Cardiogenic shock during perioperative period~7. Ventricular assist device use~8. cannot communication because of a language barrier or illiteracy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- dexmedetomidine (Type: EXPERIMENTAL): dexmedetomidine, 0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
- control (Type: PLACEBO_COMPARATOR): saline, same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol~* Meet all of the following criteria in at least one eye: Have more than 10 lashes with collarettes present on the upper lid; have at least mild erythema of the upper eyelid margin; have an average Demodex density, upper and lower eyelids combined, of 1.5 or more mites per lash~Exclusion Criteria:~* Have used lid hygiene products within 14 days of Screening or unwilling to forego the use of lid hygiene products during the study~* Have used a prostaglandin analogue to promote eyelash growth within 30 days of Screening or any plans to initiate treatment during the study~* Have used artificial eyelashes or eyelash extensions within 7 days of Screening or be unwilling to forego their use during the study~* Be pregnant or lactating at the time of Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day for approximately 43 days
- Control (Type: PLACEBO_COMPARATOR): Vehicle of TP-03 ophthalmic solution, administered topically twice a day for approximately 43 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mifepristone Versus Laminaria for Cervical Ripening in Midtrimester Induction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* pregnant women with fetal anomalies, aneuploidy, or demise at 15-22 weeks gestation~* age greater than 16~* able to speak English~Exclusion Criteria:~* prior uterine scar or~* allergy or history of bad reaction to any of the study drugs or~* history of chronic adrenal failure or~* porphyria or~* concurrent long-term corticosteroid treatment

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/=18 years of age~* Chronic hepatitis C infection for at least 6 months duration~* Hepatitis C genotype 1a or 1b~* Patients must have discontinued prior hepatitis C treatment at least 12 weeks prior to enrollment in this study~* Patient showed a previous null response to therapy as defined by \< 2 log10 IU/mL decrease in viral titer after at least 12 weeks of treatment with PEG-IFN/RBV~Exclusion Criteria:~* Hepatitis C infection with a genotype other than genotype 1a or 1b~* Body mass index \<18 or \>/=36~* Hepatitis A, hepatitis B, or HIV infection~* Herbal remedies \</=1 month prior to the first dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm A (Type: EXPERIMENTAL): 24 weeks of therapy with mericitabine 1000 mg twice a day (BID), boceprevir 800 mg three times daily (TID), Pegasys 180 microgram/week, and Copegus 1000/1200 mg/day (total treatment duration of 24 weeks), followed by a 24-week treatment-free follow-up period.
- Treatment Arm B (Type: EXPERIMENTAL): 24 weeks of therapy with mericitabine + boceprevir + Pegasys/Copegus followed by 24 weeks of therapy with boceprevir + Pegasys/Copegus (triple) (total treatment duration of 48 weeks), followed by a 24-week treatment-free follow-up period.
- Treatment Arm C (Control) (Type: ACTIVE_COMPARATOR): 4 weeks of therapy with mericitabine placebo, boceprevir placebo + Pegasys/Copegus, then 20 weeks of therapy with mericitabine placebo + boceprevir + Pegasys/Copegus, then 24 weeks of therapy with boceprevir + Pegasys/Copegus (total treatment duration of 48 weeks), followed by a 24-week treatment-free follow-up period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Rewire Study (Mindfulness Mobile App to Reduce Adolescent Substance Use)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ages 13 to 18~* involved with Juvenile Justice system~* documented substance use~* English-speaking~* living in the community~Exclusion Criteria:~* non English-speaking~* living in treatment or detention facility

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- App Evaluation (Type: EXPERIMENTAL): All 60 teens in The Rewire Study will complete the first 4 modules of the Rewire app. Prior to using the app, they will complete a baseline assessment. Follow up surveys will be completed at 2 weeks and 8 weeks post-baseline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Non-Inferiority of Airmod to Capnostream™35

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of signed and dated informed consent form.~2. Stated willingness to comply with all study procedures and availability for the duration of the study.~3. Male or female with at least 20 years of age.~4. Fit for intravenous general anesthesia (IVG) as assessed by pre-anesthesia evaluation.~Exclusion Criteria:~1. Presence of neck pain or injuries.~2. Under the use of high-flow nasal cannula ventilation. Patients with advanced airway management equipment. (For instance, Supraglottic airway device, LMA, Endotracheal tube.) Some equipment, such as High Flow Nasal Cannula (HFNC), CPAP, suction machine, could continually make noise in the patient's airway, affecting auscultation and RR measurement.~3. Unable to wear Airmod and Capnostream™35 device related accessories at the investigator's discretion.~4. As a vulnerable population, including legal incapacity or evidence that a subject cannot understand the purpose and risks of the study, regardless of authorized representative support.~5. Unwilling or unable to comply fully with study procedures (including non-toleration of the capnography cannula) due to any disease condition which can raise doubt about compliance and influencing the study outcome.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Airmod (Type: EXPERIMENTAL): The experimental device are installed in the same patient as the reference device to compare the non-inferiority of the respiratory rate measurement.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete